The company also posted its scientific poster abstract presentation at the conference. The abstract summarized cumulative preliminary data from three different pilot/observational scientific human clinical trials, and pharma like validation of its dietary supplement Renadyl™. The company also participated in the 3rd World Congress on Targeting Gut Microbiota towards clinical revolution which was held at the Pasteur Institute, Paris from Oct 21-23. Representing Kibow, Dr. Natarajan Ranganathan gave an oral presentation on the same "Enteric Dialysis Concept" and Gut-Kidney connection. The presentation was well received and recognized among all the medical, scientific, and clinical researchers from several countries. Renadyl™, a probiotic and prebiotic dietary supplement, is currently sold via Kibow's own online store (www.renadyl.com or www.kibowbiotech.com). This probiotic dietary supplement is known for its ability to target and help reduce the buildup of uremic toxins in the body, thus helping to maintain healthy kidney function, via Kibow's Uremic Toxin Reduction Technology. The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA.
In addition to marketing and sales of Renadyl™ as a dietary supplement, the company is currently exploring the option of advancing the product to prescription drug status by way of adhering to all USFDA guidelines. This will mandate obtaining the needed Investigator New Drug (IND) process and accomplishing several additional human Randomized Controlled Trials (RCT) in the forthcoming years in USA and possibly in several other countries. As a prescription drug, the product will gain greater acceptance by healthcare professionals and equally increased potential for marketing and sales towards Chronic Kidney Disease applications worldwide. About Kibow Biotech: Established in 1997, Kibow Biotech specializes in research and development of probiotic/prebiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to the governmental rules and regulatory authorities of individual countries. About Uremic Toxin Reduction Technology – Also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics. Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Investor & Media Contact: N. Ranganathan (610) 353 5130) or Email www.kibowbiotech.com Original Source Comments are closed.
|
Categories
All
Archives
December 2022
|
RSS Feed